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Abstract Cell fusions are important to fertilization, pla-
centation, development of skeletal muscle and bone, cal-
cium homeostasis and the immune defense system.
Additionally, cell fusions participate in tissue repair and
may be important to cancer development and progression.
A large number of factors appear to regulate cell fusions,
including receptors and ligands, membrane domain orga-
nizing proteins, proteases, signaling molecules and fuso-
genic proteins forming alpha-helical bundles that bring
membranes close together. The syncytin family of proteins
represent true fusogens and the founding member, syncy-
tin-1, has been documented to be involved in fusions
between placental trophoblasts, between cancer cells and
between cancer cells and host cells. We review the litera-
ture with emphasis on the syncytin family and propose that
syncytins may represent universal fusogens in primates and
rodents, which work together with a number of other pro-
teins to regulate the cell fusion machinery.
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Cell fusions in the developing mammal
The fusion between the sperm and the egg marks the begin-
ning of a new individual and ensuing development of either
man or beast depends upon a number of additional cell
fusion events (reviewed by Ogle et al. 2005). Thus, mono-
nuclear cytotrophoblasts fuse to form the syncytiotropho-
blast layer of the placenta in man and certain other
mammals. Syncytiotrophoblasts control the exchange of
gases, nutrients and waste products between the fetus and
the mother, protect the fetus against the maternal immune
system and are also responsible for the production of hor-
mones, which like chorionic gonadotropin, regulate the
continuation of pregnancy. In addition, in the developing
individual, myoblasts fuse to form multinucleated skeletal
muscle Wbers, while cells of monocytic origin fuse to form
osteoclasts, which participate in bone sculpturing and
remodeling as well as in the regulation of serum calcium
concentrations.
Cell fusions contribute to tissue repair
It is well-known that skeletal muscle is regenerated through
fusion of muscle Wbers with satellite cells (BischoV 1994)
and that macrophages may fuse to form multinucleated
giant cells with enhanced phagocytic capabilities in
response to injury and antigenic challenges (Vignery 2005).
Recent data indicate that additional cell fusions may con-
tribute to tissue repair in the adult (Vassilopoulos et al.
2003; Wang et al. 2003). Bone-marrow-derived (BMD)
cells have been shown to fuse with hepatic cells, nerve cells
and gastrointestinal cells and the theory has been put for-
ward that such fusions may serve to repair damaged or cor-
rupted cells (Alvarez-Dolado et al. 2003; Rizvi et al. 2006;
Vassilopoulos et al.2003; Wang et al. 2003). However, it is
still debated whether such fusions are important to tissue
repair and whether they engage BMD stem cells or more
diVerentiated fusogenic cells like monocytes/macrophages
(reviewed by Vignery 2005). Intriguingly, the accumula-
tion of macrophages in injured organs may reXect not only
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the need to remove debris but also to repair compromised
cells through heterotypic fusions (Vignery 2005). More-
over, in recent transplant experiments, irradiated mice
showed evidence of fusions between crypt stem cells and
donor BMD cells (Rizvi et al. 2006). In thus transplanted
mice, representatives of all cell lineages derived from intes-
tinal crypt stem cells (absorptive columnar, enteroendo-
crine, goblet and Paneth cells) showed expression of
chromosomal markers characterizing donor BMD cells.
This phenomenon appeared to depend upon tissue injury
since expression of donor cell markers never was detected
in non-irradiated mice (Rizvi et al. 2006). An alternative to
fusions has been suggested by Holmgren et al. (1999) and
de la Taille et al. (1999), who have demonstrated that cells
phagocytosing apoptotic cells may acquire functional
DNA. Moreover, a mechanism of cell–cell invasion (ento-
sis) was recently described and could potentially transfer
DNA between cells (Overholtzer et al. 2007). Thus, viral as
well as normal sequences from apoptotic cells have been
found to be active also in phagocytosing cells (Holmgren
et al. 1999). This observation challenges our understanding
of apoptosis as an eYcient way of clearing corrupted or
alien DNA.
Cell fusions during viral infections
Infections with enveloped viruses such as HIV-1 may also
lead to cell fusions. The viral genome encodes envelope
(Env) proteins, which bind to cell surface receptors and
assist the virus in entering the cell. The infected cell com-
mences to synthesize Env proteins, which, upon insertion in
the plasmalemma, engages receptor proteins in neighboring
cells and initiate fusions. Interestingly, modiWcations of the
cytoplasmic tail of several Env proteins appear to modify
fusions. Thus, proteolytic cleavage of the cytoplasmic tail
regulates fusions and also cellular signaling events, such as
tyrosine kinase activity, may be involved in regulation of
virally induced cell fusions (Kubo et al. 2003).
Receptor proteins may bind Env proteins from diVerent
classes of viruses. Thus, a cell infected by a speciWc virus
becomes resistant to infections with other viruses that bind
to the same receptor. This phenomenon, which probably
reXects receptor saturation, has led to the grouping of retro-
viruses into diVerent subtypes, which bind to the same
receptor. Other types of viruses encode fusogenic proteins
(like inXuenza hemagglutinin), which do not bind to surface
receptors, but which liberate a fusion peptide in the acidic
milieu of endosomes and thus initiate viral–host cell fusion
following endocytic uptake of viral particles. Both these
proteins and the Env proteins are referred to as class I viral
fusion proteins and contain hydrophobic fusion peptides
buried within their sequences. Following receptor engage-
ment or endosomal acidiWcation the fusion peptides are
liberated by proteolytic cleavage. The cleaved peptides
undergo conformational changes, resulting in hairpin-like,
alpha-helical bundles, which bring the viral and cell mem-
branes into close apposition and thereby facilitates fusion
(reviewed by Chen and Olson 2005).
Cancer–host cell fusions
In 1911 Aichel suggested that cancer cells might spontane-
ously fuse with host cells to produce hybrids with super-
numerary chromosomes that could evolve into cells of
increased malignancy. Subsequent studies have conWrmed
this prediction by demonstrating that cells with mixed phe-
notypes spontaneously appear in co-cultures of normal and
malignant cells (Barski and Cornefert 1962; Busund et al.
2002; Mortensen et al. 2004; Wakeling et al. 1994) (Figs. 1,
2,  3). Additionally, transplanted tumor cells of animal
(Busund et al. 2003; Chakraborty et al. 2000; Fortuna et al.
1990; Kerbel et al. 1983; Larizza et al. 1984a; Wiener et al.
1974a, b) or human (Goldenberg et al. 1974; Goldenberg
and Pavia 1982; Mortensen et al. 2004) origin may fuse
with and acquire phenotypic characteristics of normal host
cells (Fig. 4). In some of the in vivo studies, data suggested
that the putative fusion partner was of macrophage or endo-
thelial origin but, in most cases, deWnite identiWcation was
not achieved. In a few cases, it has also been demonstrated
that the fused cells expressed genetic markers of both
parental cell types (Goldenberg et al. 1974; Mortensen
et al. 2004; Wiener et al. 1974a, b) (Figs. 2, 3). Mortensen
et al. (2004) demonstrated that, initially after fusion, bi- or
multinucleated cells formed and that such cells had the
parental genomes seggregated in diVferent nuclei (hetero-
karyons) (Fig. 2a–e). Subsequently, mitotic Wgures
appeared showing an admixture of the parental chromo-
somes (Fig. 2f–j). Eventually, cells with the parental
genomes mixed in a single nucleus (synkaryons) were
detected (Fig. 2k–o). In agreement with the notion that syn-
karyons appear after mitotic divison of heterokaryons, syn-
karyons are usually detected in pairs (Fig. 3). A few recent
studies present compelling evidence that cells with genetic
characteristics of hybrid cells also may appear in human
tumors (Andersen et al. 2007; Chakraborty et al. 2004; Yil-
maz et al. 2005; Streubel et al. 2004). Thus, in two cases of
renal carcinomas, arising in bone marrow transplant recipi-
ents, some tumor cells showed genetic markers characterizing
the healthy donor (Chakraborty et al. 2004; Yilmaz et al.
2005). Moreover, in patients with multiple myelomas,
osteoclasts have been shown to contain an admixture of
nuclei, of which some possess tumor-speciWc chromosomal
translocations while others are devoid of translocations
(Andersen et al. 2007). Finally, lymphoma-speciWc geneticHistochem Cell Biol (2008) 129:551–561 553
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Fig. 1 Cancer–endothelial cell 
fusion. Co-culture of human 
breast cancer (MCF-7) cells and 
human umbilical vein endothe-
lial cells (HUVEC). Cells were 
stained for the cancer cell mark-
er cytokeratin (red, c), the endo-
thelial cell marker vimentin 
(green, b) and DNA (bisbenzi-
mide, blue, d). Note in the 
merged image (a) one fused, 
multinucleated cell reacting for 
both cytokeratin and vimentin 
(orange-yellow)
Fig. 2 Chromosomal markers and cell fusions. Co-cultures of human
breast cancer cells and bovine endothelial cells. The cultures were sub-
jected to Xuorescent in situ hybridization (FISH) with probes recogniz-
ing all bovine chromosomes (green;  b,  g,  l) and all human
chromosomes (red; c, h, m) and counter-stained for DNA with DAPI
(blue; d, i, n) and observed in diVerential interference contrast (DIC; e,
j, o). Merged red-green images are shown in a, f, k. Note that initially,
binuclear cells (heterokaryons) form, having one bovine and one hu-
man nucleus (a–e). Occasionally, tri- or multinuclear cells with diVer-
ent admixtures of bovine and human nuclei are also detected. At longer
times after mixing, mitotic Wgures, containing an admixture of bovine
and human chromosomes appear (f–j) and, eventually, cells with a sin-
gle nucleus, containing an admixture of the two genomes in mixture
(synkaryons) are detected (k–o)554 Histochem Cell Biol (2008) 129:551–561
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abnormalities were described in endothelial cells in B cell
lymphomas (Streubel et al. 2004). Although these data do
not formally prove that tumor–host cell hybrids did form in
these patients, the combined results from studies in vitro
and in vivo do present compelling evidence that cell fusions
do occur in tumors (reviewed by Pawelek 2005).
The essential question regarding cancer–host cell fusions
is, of course, if they are relevant to the patient. In fact, there
are two opposing views. The Wrst is based on early experi-
ments on fusions induced to occur between cancer cells and
normal cells in culture. With few exceptions, such experi-
ments revealed that malignancy was suppressed (Harris
et al.  1969; Harris 1988; Stanbridge 1976; Wiener et al.
1974a, b). These studies were, in fact, seminal to the dis-
covery of tumor suppressor genes (reviewed by Anderson
and Stanbridge 1993). Since tumor suppressor genes, like
p53 and Rb, frequently are inactivated in cancer cells,
fusions would present cancer cells with unperturbed tumor
suppressors from the normal fusion partner and conse-
quently initiate cell cycle arrest or apoptosis. Although, this
certainly applied for the cell types studied in the contribu-
tions cited above, it may not be a general rule. Thus, pro-
duction of monoclonal antibodies depends upon the fact
that it is possible to fuse antibody-producing spleen cells
with myeloma cells to obtain hybridomas that retain the
unlimited proliferative ability of the tumor cell partner and
the antibody production of the normal cell (Kohler and
Milstein  1975). In fact, several studies documented that
Fig. 3 Chromosomal markers and cell fusions. Mixed culture of hu-
man breast cancer cells and bovine endothelial cells submitted to dou-
ble FISH as in Fig. 2 (a double FISH; b combined DAPI and DIC).
Low power micrograph showing a pair of synkaryons with the bovine
and human genomes admixed in single nuclei (arrows). In addition,
nuclei hybridizing only for the bovine (green) or only for the human
(red) genome occur
Fig. 4 Cancer–host cell fusion in vivo. a, b Section from lung of a
nude mice injected with human breast cancer (MDA-MB-231) cells in
the tail vein (Mortensen et al. 2004). The section underwent FISH for
the mouse genome (red) and the human genome (green) (a) and DNA
was counterstained with DAPI (b; blue). Note one nucleus in which the
human and mouse genome co-localize (arrow). C: Similar section,
stained with an antibody detecting human (but not mouse) p53 (red;
p53 is mutated and overexpressed by the breast cancer cells), an anti-
body to beta-catenin (to mark cell membranes) and for DNA with bis-
benzimide (blue). Note a micrometastasis of human breast cancer cells
having violet (red + blue) Xuorescent nuclei. d Section stained for hu-
man p53 (red) and the endothelial marker von Willebrand factor
(green) and DNA (blue). Note a human cancer cell with a violet
(red + blue) nucleus showing membrane-staining for von Willebrand
factor. Since von Willebrand factor is not normally expressed by the
breast cancer cells, this image is suggestive of a fusion between a
human breast cancer cell and a mouse endothelial cell. Similar results
were obtained using double FISH for the human and mouse genome
and imunoXuorescent staining for von Willebrand factor (described by
Mortensen et al. 2004)Histochem Cell Biol (2008) 129:551–561 555
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some fusions may lead to cells of increased malignancy
(Barski and Cornefert 1962; Busund et al. 2003; Chakr-
aborty et al. 2001; De Baetselier et al. 1981; Kerbel et al.
1983; Larizza et al. 1984b; Pawelek 2000; Rachkovsky
et al. 1998). Possibly, the genetic make-up of tumors may
dictate the outcome of individual cancer–host cell fusions.
Moreover, fusions lead to aneuploidy and chromosomal
instability, which characterizes most cancers and may, by
itself, stimulate carcinogenesis (Duelli et al. 2007).
Mechanisms behind cell–cell fusions
Fusions between normal cells
Cell fusion events must be extremely well controlled. Due
to their major importance to fertilization, placentation,
muscle development, bone structure, calcium homeostasis
and the immune defense system, much eVort has gone into
elucidating mechanisms underlying cell–cell fusions. Addi-
tionally, the potential role of cell fusions as a repair mecha-
nism and the role of cell fusions in cancer development and
progression have further stimulated research in this Weld. In
spite of this, much less is known about cell–cell fusion
mechanisms than is known about how intracellular mem-
branes fuse through v- and t-SNAREs. Interestingly, engi-
neered Xipping of the v- and t-SNARE machinery has been
shown to promote cell–cell fusions (Weber et al. 1998).
However, it is evident that this mechanism is not a physio-
logical mediator of cell–cell fusions. Interestingly, v- and t-
SNAREs act similar to class I viral fusion proteins in that
they form bundles of alpha-helices, which result in mem-
brane apposition and fusion (Blumenthal et al. 2003; Jahn
et al. 2003). Of the many proteins, which to date have been
shown (or proposed) to be involved in cell fusions in mam-
mals, only the syncytin family appears to use a similar
alpha-helical mechanism. That they do is not surprising in
view of the fact that syncytins represent conserved
endogenous retroviral Env sequences. The founding family
member, syncytin-1, was discovered as a protein capable
of mediating fusions between cytotrophoblasts into
syncytiotrophoblasts (Blond et al. 2000; Mi et al. 2000).
This capability may have contributed to a high degree of
evolutionary conservation of the syncytin-1 sequence.
Syncytin-1 represents the Env protein of the human
endogenous retroviral (HERV) W sequence, which entered
the primate genome 25–40 million years ago. In contrast,
most other retroviral sequences inserted in our genome
have been subject to inactivating changes and probably rep-
resent garbage sequences. Molecular studies have shown
that syncytin-1 (Env W) shares a structure similar to class I
viral fusion proteins, especially in the region of the N- and
C-terminal heptad repeats (NHR and CHR), and shares a
common fusion mechanism with these proteins (Chang
et al. 2004; Gong et al. 2005). A synthetic peptide derived
from the CHR is also capable of inhibiting syncytin-1-med-
iated fusions by perturbing this mechanism (Chang et al.
2004). Syncytin-1 binds to the D-type retroviral receptor
ASCT-2 (Blond et al. 2000) and may use another neutral
amino acid transporter (ASCT-1) as an auxiliary receptor
(Lavillette et al. 2000). Syncytin antibodies, syncytin-1
downregulation through antisense oligonucleotides and the
syncytin-1 CHR peptide have been shown to inhibit fusions
between trophoblast-derived cells (Blond et al. 2000;
Chang et al. 2004; Mi et al. 2000). Agents increasing cellu-
lar levels of cAMP or cAMP analogues have been shown to
promote cytotrophoblast fusions in vitro (Keryer et al.
1998) and such agents are also known to elevate protein
and mRNA levels of syncytin-1 in isolated cytotrophoblasts
(Frendo et al. 2003). Also estradiol may regulate syncytin-1
expression (Carino et al. 2003) and the placenta-speciWc
transcription factor GCMa interacts with two upstream sites
in the HERV-W 5-long terminal repeat and stimulates
syncytin-1 transcription (Yu et al. 2002). Additionally,
experimentally induced truncations in the cytoplasmic tail
of syncytin-1 increases its fusogenicity (Drewlo et al.
2006), similar to what has been observed for some virally
derived Env proteins (reviewed by Kubo et al. 2003). How-
ever, if modiWcations in the cytoplasmic tail of syncytin-1
are of physiological importance for regulating fusogenicity
has yet to be demonstrated.
A second syncytin-family member, syncytin-2, was sub-
sequently found also to be expressed in the placenta (Blaise
et al. 2003). Syncytin-2 also represents a highly conserved
endogenous retroviral envelope gene and is derived from
the HERV FRD sequence (Blaise et al. 2003). Immuno-
cytochemical studies have localized syncytin-1 primarily to
syncytiotrophoblasts as well as to cytotrophoblasts (Fig. 5).
The exact localization is somewhat controversial (reviewed
Fig. 5 Human term placenta immunocytochemically stained with a
syncytin-1 peptide antiserum. Staining occurs in the syncytiotropho-
blasts, which predominate at this stage. Nuclei are lightly counter-
stained with haematoxylin556 Histochem Cell Biol (2008) 129:551–561
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by Potgens et al. 2004), which may reXect diVerences in
antibodies, Wxation procedures and controls. A major point
of concern is also the degree of cross-reactivity to the
related sequences in syncytin-2, which recently was
localized to a subpopulation of cytotrophoblasts (Malassiné
et al. 2008). The syncytin-1 receptor protein ASCT-2 was
recently localized to cytotrophoblasts (Hayward et al.
2007). More studies on the exact distribution of syncytin
expression in the placenta using syncytin-1 and -2 speciWc
antibodies seem warranted in order to exactly localize
where fusions are likely to occur.
Trophoblast cell fusions are, however, not unique to the
primate placenta. Thus, also in the mouse placenta, tropho-
blasts fuse to form syncytiotrophoblasts but mice do, of
course, not express HERV sequences. Amazingly, an in-
silico search of the mouse genome unraveled the existence
of two murine endogenous retroviral (MERV) Env genes,
labeled syncytin-A and -B (Dupresssoir et al. 2005). These
genes were also fusogenic and orthologous genes were
present in additional species of muridae (rats, gerbils, voles
and hamsters) and appear to have entered the rodent lineage
some 20 million years ago (Dupresssoir et al. 2005). They
were expressed in the placenta and at least syncytin-A has
been shown to be involved in the formation of syncytio-
trophoblasts in mice (Gong et al. 2007). This represents an
amazing example of parallel acquisition of retroviral genes
of importance to reproduction in primates and rodents and
poses the question whether also other species may have
acquired similar viral genes of importance to cell fusions.
The ability of syncytins to induce cell fusions may not be
their only physiologic role. Thus, recent studies have
shown that while syncytin-2 and syncytin-B also possess
immunosuppressive activity, syncytin-1 and syncytin-A do
not (Mangeney et al. 2007). Syncytin-1 expression was
originally detected in the placenta and testis (Blond et al.
2000; Mi et al. 2000) but subsequent studies have revealed
the presence of syncytin-1 also in the brain (Antony et al.
2004) and in breast, colon and endometrial cancers
(Bjerregaard et al. 2006; Strick et al. 2007, Larsen, Talts,
Andersen, Bjerregaard and Larsson: work in progress).
Syncytin-1 may also regulate production of inXammatory
mediators (Antony et al. 2004).
A number of additional molecules have been shown to be
important to cell fusions. In fact, in all systems studied so
far, from mating yeast to man, a bewildering array of mech-
anisms have been identiWed (see Chen and Olson 2005;
Chen et al. 2007; Oren-Suissa and Podbilewicz 2007 for
recent reviews). Molecules potentially involved in mamma-
lian cell fusions include ADAM (a disintegrin and metallo-
proteinase domain) 12 (meltrin alpha), which has been
associated with myoblast and osteoclast cell fusions (Abe
et al.  1999; Galliano et al. 2000; Gilpin et al. 1998;
Yagami-Hiromasa et al. 1995). In addition, ADAMs 1 and
2 (fertilins) may be involved in sperm–oocyte fusions, but
do not seem indispensable for this function and, in man, the
fertilin alpha gene is dysfunctional (Chen and Olson 2005;
Cho et al. 1997, 1998, Evans et al. 1998; Jury et al. 1997,
1998). In contrast, the tetraspanin protein CD9 is needed for
sperm–oocyte fusions (Le Naour et al. 2000). CD9 is also
expressed by BeWo trophoblast tumor (choriocarcinoma)
cells and has been linked both to BeWo invasiveness and to
invasion during mouse embryo implantation (Hirano et al.
1999; Liu et al. 2006). CD9 has, together with another tetra-
spanin family member, CD81, also been linked to myoblast
fusion and myotube maintenance (Tachibana and Hemler
1999). Moreover, antibodies to either CD9 or CD81 have
been shown to block fusions induced by Mason—PWzer
monkey virus—a D-type retrovirus (Duelli et al. 2005).
Tetraspanins are known to organize other proteins into
membrane microdomains and may link to the actin cyto-
skeleton via EWI (Glu-Trp-Ile) and ERM (ezrin–radixin–
moesin) proteins (Hemler 2003; Sala-Valdés et al. 2006).
Possibly, their role as organizers of other proteins into
microdomains may play a role in their involvement with
cell fusions (Zivyat et al. 2006). They do not express char-
acteristics of fusogenic proteins like the syncytins, SNAREs
and class I viral envelope proteins, but are coexpressed with
syncytin-1, at least in BeWo cells. A macrophage fusion
receptor (MFR, SIRPalpha), resembling CD4–the cell sur-
face receptor for HIV—has been identiWed in macrophages
(Saginario et al. 1995,  1998; van den Berg et al. 2005).
MFR, which belongs to the immunoglobulin superfamily,
binds another member of this family, CD47. CD47 is also
structurally related to proteins expressed by Vaccinia and
Variola viruses (Chen et al. 2007). Whereas expression of
MFR is restricted to myeloid cells and neurons, CD47 is
ubiquitously expressed. MFR is transiently induced in mac-
rophages at the onset of fusion while CD47 expression is
constant. It has been hypothesized that CD47 initially binds
to a long form of MFR to secure recognition and then
switches to bind a shorter form to bring the plasma mem-
branes closer (5–10 nm) for fusion (Vignery 2005). Addi-
tionally, or alternatively, CD47 may promote calcium entry
by forming a membrane pore (reviewed in Chen et al.
2007). Also the hyaluronan receptor, CD44, is induced tran-
siently when macrophages start to fuse. CD44 and MFR are
subsequently cleaved by proteases during fusion. As men-
tioned above, CD9 and CD81 may also contribute to macro-
phage fusion. Additionally, DC-STAMP seems to be
required for macrophage fusions. Mice lacking DC-STAMP
are osteopetrotic and lack multinucleated osteoclasts and
giant cells (Yagi et al. 2005). DC-STAMP is a seven-trans-
membrane receptor, somewhat similar to the HIV co-recep-
tor CXCR4, but a ligand has yet to be identiWed.
These and many more molecules, including integrins,
vacuolar ATPase and receptors and their ligands, as well asHistochem Cell Biol (2008) 129:551–561 557
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diVerent signaling intermediates have been associated with
cell fusions. With the exception of the syncytins, most of
the mammalian molecules so far studied do not fulWll strict
criteria for fusogens and several are dispensable for fusions
(reviewed by Chen and Olson 2005; Chen et al. 2007;
Oren-Suissa and Podbilewicz 2007) .  H o w e v e r ,  t h i s  m a y
reXect molecular redundancy and does not deWnitely
exclude that these molecules may participate in fusions. It
is noteworthy that, in both man and mouse, two diVerent
syncytins are expressed and are both fusogenic. It is possi-
ble that, in the mammalian system, fusion requires a Xotilla
of molecules organized into membrane microdomains by
proteins like CD9, encompassing receptors/ligands, signal-
ing entities, proteases and fusogens of retroviral origin that
are capable of forming alpha-helical bundles, which bring
membranes closer. Syncytins and related retroviral enve-
lope sequences may, in this connection, function both as
fusogens and receptor ligands. However, it seems unlikely
that as irreversible an event as a cell–cell fusion should
depend upon a single receptor–ligand interaction. Thus,
both facilitatory and inhibitory factors are expected to be
part of the Xotilla.
Cancer cell fusions
Studies by Mortensen et al. (2004) documented that human
breast cancer cells fused with endothelial cells in culture.
Stimulated by studies showing that syncytin-1 was
involved in cytotrophoblast cell fusions (Blond et al. 2000;
Mi et al. 2000), we examined whether a similar mechanism
could account for cancer–endothelial cell fusions. Expres-
sion of syncytin-1 was documented in the breast cancer cell
lines examined (MCF-7 and MDA-MB-231 cells; Bjerreg-
aard et al. 2006, SK-BR-3 cells: Talts, Bjerregaard and
Larsson: unpublished data). Moreover, we found that both
tumor cells and endothelial cells expressed the syncytin-1
receptor ASCT-2. Use of phosphorthioate-protected syncy-
tin-1 antisense oligonucleotides downmodulated syncytin-1
expression as measured by either quantitative RT-PCR or
Western blotting and inhibited breast cancer–endothelial
cell fusions, whereas a scrambled oligonucleotide control
was without eVect. Additionally, the syncytin-1 CHR pep-
tide, referred to above, also inhibited the fusions whereas a
control peptide was without eVect (Bjerregaard et al. 2006).
However, neither the antisense nor the CHR peptide exper-
iments eVected a total inhibition of cancer-endothelial cell
fusions. There may be several reasons to this. Thus, the
antisense oligonucleotide did not totally downmodulate
syncytin-1 levels and could therefore not be expected to
decrease cell fusions to zero and the lack of total inhibition
by the CHR peptide could potentially be ascribed to proteo-
lytic degradation. However, we also detected that the breast
cancer cells produced syncytin-2 and cannot exclude that
also this molecule contributed to the cancer–host cell
fusions. Further experiments using shRNA-directed down-
modulation of both syncytin-1 and -2 as well as of addi-
tional putative fusogenic retroviral sequence are now
underway to test this. Nevertheless, these data provide
strong evidence that syncytin-1 is involved in mediating
cancer–endothelial cell fusions in vitro.
We next examined two series of human breast cancer
patients for tumoral expression of syncytin-1 using a poly-
clonal antiserum raised to a synthetic nonapeptide derived
from the syncytin-1 sequence. In addition, tumors were also
screened for expression of ASCT-2 using a peptide antise-
rum. Preabsorption of the antisera with the corresponding
peptides, but not with irrelevant peptides, abolished stain-
ing (Larsson et al. 2007b) (Fig. 6). The results showed that
38% of all breast cancer samples showed detectable stain-
ing for syncytin and that endothelial cells expressed ASCT-
2 (Fig. 6). Moreover, signiWcant expression of ASCT-2 was
detected also in many tumor cells (Fig. 6). The degree of
syncytin immunostaining was visually graded using coded
specimens and statistical analysis showed that it correlated
positively with disease-free survival of the patients (Lars-
son et al. 2007b). Multivariate analysis included age dichot-
omized at 40 years, tumor size dichotomized at 20 mm,
grade and adjuvant therapy and identiWed syncytin expres-
sion as an independent prognostic indicator of increased
disease-free survival Also when used as a continuous vari-
able, syncytin expression emerged as a signiWcant prognos-
tic indicator for disease-free survival in the Cox model
(P = 0.02) (Larsson et al. 2007b).
The involvement of syncytin-1 in tumor cell fusion
events was subsequently conWrmed by Strick et al. (2007),
working with endometrial carcinomas. In their study,
downmodulation of synctytin-1 expression also inhibited
fusions between endometrial tumor cells. In agreement with
Wndings on placental cells (vide supra), both cAMP elevating
agents and estrogens upregulated syncytin-1 expression.
However, only cAMP elevating agents stimulated cell
fusions (Strick et al. 2007). This apparent discrepancy may
possibly be ascribed to the fact that estrogen treatment
upregulated TGFbeta, which interfered with syncytin-
induced fusions. Thus, estrogen did, in fact, stimulate cell
fusions if TGFbeta was immunoneutralized. Conversely,
additions of TGFbeta 1 or 3 reduced fusions induced by
cAMP-elevating agents. This eVect was observed both in
endometrial carcinoma cells and in trophoblast-derived
cells. These results show that both cAMP and estrogens
positively may regulate syncytin-1 expression in tumor
cells and that the TGFbeta family may negatively regulate
the fusogenic eVects of syncytin-1 in both trophoblasts and
cancer cells (Strick et al. 2007).
The role of syncytin-1 and cell fusions in cancer needs
further study. Thus, our data show that syncytin-1 is not558 Histochem Cell Biol (2008) 129:551–561
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the only fusogenic protein expressed by breast cancer cells
and the results presented by Strick et al. (2007) show that
additional regulators, such as TGFbeta isoforms may be
important modulators of cell fusions. So far, our breast
cancer data indicate that syncytin-1 expression constitutes
a positive prognostic factor. This is not the same as to say
that cell fusions may be universally beneWcial to cancers.
First, syncytins may have additional eVects within the
tumor environment (Larsson et al. 2007a, b). Secondly, it
seems likely that several factors within the cancer and its
stroma (inactivated tumor suppressor genes, activated
oncogenes, expression of fusogens and of CD9 and CD81
as well as TGFbeta) may act together to bring about a
tumor proWle that may be as diverse as the one demon-
strated by the cell fusion experiments referred to above.
Interestingly, however, expression of CD9 has been ana-
lyzed in a number of tumors and seems, like syncytin
expression, to predict a good prognosis (Funakoshi et al.
2003; Hashida et al. 2002; Higashiyama et al. 1997; Houle
et al. 2002; Miyake et al. 1995; Uchida et al. 1999). We
propose that syncytins may be fusogens of importance to
both trophoblast and cancer cell fusions and that they pos-
sibly also may mediate additional cell fusion events, acting
in concert with other molecules with both enhancing and
inhibitory regulatory eVects.
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